P&T COMMUNITY
 
MediMedia Managed Markets
Our
Other
Journal
Managed Care magazine
Login / Register
Join Us  Facebook  Twitter  Linked In
About P&T Journal
Contacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
    Vice President, Group Publisher

Production: Mary Ellen Curry,
    Director of Production Services

Circulation: Jackie Ott, Circulation Manager


Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints


Recent Issues

May 2010

Features

Commentary

New Directions for Health Care Law in the U.S.

Emphasis on Preventive, Holistic Therapies Offers Possibilities for Pharmacists

The passage of the Patient Protection and Affordable Care Act represents an opportunity to begin repairing parts of our health care system. For example, pharmacists might be able to expand their scope of practice and become more involved with patients and prescribers. However, several roadblocks, including a lack of funding and some ambiguous congressional language, must first be overcome.
Stephen Barlas

Drug Review

Lisdexamfetamine Dimesylate (Vyvanse), A Prodrug Stimulant for Attention-Deficit/Hyperactivity Disorder

As a first-line therapy for adults and children 6 to 12 years of age for ADHD, LDX is associated with a lower daily average use, less need for augmenting the dose, and better persistence with therapy compared with other long-acting drugs. Dr. Goodman reviews the drug’s history, benefits and risks, labeling for abuse potential, adverse events, and overall safety profile.
David W. Goodman, MD

Pharmaceutical Approval Update

Drugs discussed include carglumic acid tablets (Carbaglu) for children and adults with excessive ammonia levels; adapalene topical 0.1% lotion (Differin) for patients with acne vulgaris; and velaglucerase alfa for injection (VPRIV), an enzyme replacement therapy for pediatric and adult patients with type-1 Gaucher disease.
Marvin M. Goldenberg, PhD, RPh, MS

Meeting Highlights

American College of Cardiology, 59th Annual Scientific Session

Topics include therapies for blood pressure and lipids in the ACCORD trial, betrixaban versus warfarin for atrial fibrillation, the use of low-osmolar contrast agents in invasive cardiac catheterization, early clopidogrel and eptifibatide for acute coronary ­syndromes, a new formulation of diazoxide choline for hypertriglyceridemia, and a rosuvastatin/ezetimibe combination for reducing lipid levels.
Walter Alexander

Departments

Editorial

Understanding the Quality Debate In Health Care

David B. Nash, MD, MBA, discusses the quality debate in health care: the U.S. excels in the high-tech arena, but we must find new ways to compensate physicians and provide better patient access to care.
David B. Nash, MD, MBA

Medication Errors

Pen Injector Technology Is Not without 'Impending' Risks

Matthew Grissinger, RPh, FASCP, explains how to ensure the safe use of pen injectors by medical personnel and by patients at home.
Matthew Grissinger, RPh, FASCP

Prescription: Washington

With Health Care Reform Out of the Way, Congress Can Now Confront Drug Safety

Stephen Barlas reviews two bills that would improve the safety of drug ingredients and prevent counterfeit drugs from entering the U.S.
Stephen Barlas

Drugs/Drug News/New Medical Devices

P&T presents the latest FDA approvals, drug indications, recalls, and industry updates.

Drug Forecast

Milnacipran (Savella), a Treatment ­Option for Fibromyalgia

Milnacipran (Savella) for fibromyalgia is reviewed.
Clayton English, PharmD; Jose A. Rey, PharmD, BCPP; and Chabely Rufin, PharmD Candidate